BOSTON, June 16, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (formerly, 1532139 B.C. Ltd) (the "Corporation") is pleased to announce the completion of a business combination transaction (the "Transaction") with GuideAI Health, Inc. ("Guide Health"). The Transaction was completed by way of plan of arrangement under the Business Corporations Act (British Columbia) under which a wholly-owned subsidiary of the Corporation acquired all of the issued and outstanding securities of Guide Health. The Corporation has also filed and obtained a receipt for its final non-offering prospectus dated June 12, 2026 (the "Prospectus") filed with the securities regulatory authorities in British Columbia, Alberta and Ontario, qualifying the distribution of Subscription Receipts under the Offering (as those terms are defined below). In connection with closing of the Transaction, the Corporation changed its corporate name to "GuideAI Health Corp.". Immediately following the closing of the Transaction and the Offering (as defined below), the Corporation had an aggregate of 53,551,525 common shares ("Common Shares") issued and outstanding.
The Corporation has obtained conditional approval of Cboe Canada (the "Exchange") for the listing of its Common Shares. Listing remains subject to the Corporation fulfilling all of the customary requirements of the Exchange, including the receipt of all required documentation.
The Transaction marks a significant milestone in the Corporation's mission to develop and deploy artificial intelligence solutions that improve the detection and management of vascular and cardiovascular disease.
"Our vision is to make advanced vascular and cardiovascular intelligence available to every healthcare provider, not just major academic centers", said Luke Higgins, Chief Operating Officer and Chief Medical Officer of the Corporation. "We believe artificial intelligence can help identify diseases earlier, connect patients to the right care faster, and ultimately improve outcomes across the healthcare system. This milestone provides the foundation to scale our technology, expand our clinical impact, and continue building a durable healthcare AI company."
Concurrent Financing
In connection with the Transaction, the Corporation completed a brokered private placement (the "Offering") of an aggregate of 5,150,000 subscription receipts (the "Subscription Receipts") at an issue price of $1.00 per Subscription Receipt for ...
